Assessment of the clinical and virological protection provided by a commercial inactivated bovine viral diarrhoea virus genotype 1 vaccine against a BVDV genotype 2 challenge.
A new genotype of bovine viral diarrhoea virus (BVDV), designated BVDV-2, has emerged in the last decade and in recent years the prevalence of BVDV-2 strains has increased. A vaccination-challenge study was carried out to determine the cross-protective efficacy of a commercial inactivated vaccine containing a BVDV-1 strain. A group of five BVDV-free calves was vaccinated twice and a second group of five calves served as negative controls. Two months after the first vaccination, all the calves were challenged intranasally with BVDV-2 strain BVD890. The clinical signs of disease, the changes in haematological variables and the level of viraemia were significantly less in the vaccinated group.
D000818:Animals; D001912:Bovine Virus Diarrhea-Mucosal Disease / Q000517:prevention & control*; D002417:Cattle; D030241:Diarrhea Virus 1, Bovine Viral / Q000235:genetics* / Q000302:isolation & purification; D005838:Genotype; D008297:Male; D015164:Vaccines, Inactivated; D014765:Viral Vaccines / Q000627:therapeutic use*
D015164:Vaccines, Inactivated; D014765:Viral Vaccines